Switch theme
Sign up to access all valuation multiples
Euroapi SA develops, manufactures, markets, and distributes Active Pharmaceutical Ingredients (APIs) and Intermediates used in the formulation of medicines for human and veterinary use, both from originators, generics, and cosmetics. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates (morphine, codeine, thebaine, etc.), analgesics, etc. It also offers Contract Development Manufacturing Organization (CDMO) services to its customers. Geographically, the company generates maximum revenue from Europe, followed by North America, Asia-Pacific, and the Rest of the world.
2020
3.4K+
LTM Revenue $1.0B
LTM EBITDA $68.4M
$309M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Euroapi has a last 12-month revenue (LTM) of $1.0B and a last 12-month EBITDA of $68.4M.
In the most recent fiscal year, Euroapi achieved revenue of $1.0B and an EBITDA of -$47.7M.
Euroapi expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Euroapi valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.0B | XXX | $1.0B | XXX | XXX | XXX |
| Gross Profit | $163M | XXX | $160M | XXX | XXX | XXX |
| Gross Margin | 16% | XXX | 15% | XXX | XXX | XXX |
| EBITDA | $68.4M | XXX | -$47.7M | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | -5% | XXX | XXX | XXX |
| EBIT | -$16.6M | XXX | -$9.4M | XXX | XXX | XXX |
| EBIT Margin | -2% | XXX | -1% | XXX | XXX | XXX |
| Net Profit | -$118M | XXX | -$147M | XXX | XXX | XXX |
| Net Margin | -12% | XXX | -14% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Euroapi's stock price is EUR 3 (or $3).
Euroapi has current market cap of EUR 285M (or $320M), and EV of EUR 275M (or $309M).
See Euroapi trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $309M | $320M | XXX | XXX | XXX | XXX | $-0.48 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Euroapi has market cap of $320M and EV of $309M.
Euroapi's trades at 0.3x EV/Revenue multiple, and -6.5x EV/EBITDA.
Equity research analysts estimate Euroapi's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Euroapi has a P/E ratio of -2.7x.
See valuation multiples for Euroapi and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $320M | XXX | $320M | XXX | XXX | XXX |
| EV (current) | $309M | XXX | $309M | XXX | XXX | XXX |
| EV/Revenue | 0.3x | XXX | 0.3x | XXX | XXX | XXX |
| EV/EBITDA | 4.5x | XXX | -6.5x | XXX | XXX | XXX |
| EV/EBIT | -18.6x | XXX | -32.7x | XXX | XXX | XXX |
| EV/Gross Profit | 1.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.7x | XXX | -2.2x | XXX | XXX | XXX |
| EV/FCF | 16.4x | XXX | 18.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEuroapi's last 12 month revenue growth is -3%
Euroapi's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $49K for the same period.
Euroapi's rule of 40 is 4% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Euroapi's rule of X is 0% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Euroapi and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -3% | XXX | -3% | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | -5% | XXX | XXX | XXX |
| EBITDA Growth | 32% | XXX | 0% | XXX | XXX | XXX |
| Rule of 40 | 4% | XXX | -7% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 0% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $49K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 16% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Euroapi acquired XXX companies to date.
Last acquisition by Euroapi was XXXXXXXX, XXXXX XXXXX XXXXXX . Euroapi acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Euroapi founded? | Euroapi was founded in 2020. |
| Where is Euroapi headquartered? | Euroapi is headquartered in France. |
| How many employees does Euroapi have? | As of today, Euroapi has 3.4K+ employees. |
| Is Euroapi publicy listed? | Yes, Euroapi is a public company listed on PAR. |
| What is the stock symbol of Euroapi? | Euroapi trades under EAPI ticker. |
| When did Euroapi go public? | Euroapi went public in 2022. |
| Who are competitors of Euroapi? | Similar companies to Euroapi include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Euroapi? | Euroapi's current market cap is $320M |
| What is the current revenue of Euroapi? | Euroapi's last 12 months revenue is $1.0B. |
| What is the current revenue growth of Euroapi? | Euroapi revenue growth (NTM/LTM) is -3%. |
| What is the current EV/Revenue multiple of Euroapi? | Current revenue multiple of Euroapi is 0.3x. |
| Is Euroapi profitable? | Yes, Euroapi is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Euroapi? | Euroapi's last 12 months EBITDA is $68.4M. |
| What is Euroapi's EBITDA margin? | Euroapi's last 12 months EBITDA margin is 7%. |
| What is the current EV/EBITDA multiple of Euroapi? | Current EBITDA multiple of Euroapi is 4.5x. |
| What is the current FCF of Euroapi? | Euroapi's last 12 months FCF is $18.8M. |
| What is Euroapi's FCF margin? | Euroapi's last 12 months FCF margin is 2%. |
| What is the current EV/FCF multiple of Euroapi? | Current FCF multiple of Euroapi is 16.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
